Running summarizing tools on a new article

Check the paper below, then start its synthesis.


Urine‐Derived Neuronal Extracellular Vesicle α ‐Synuclein Seed Amplification Assay for Synucleinopathies: A Non‐Invasive Biomarker Study

Hoang S. Tran (Hallym University, Hallym University Sacred Heart Hospital), Hữu Đạt Nguyễn (Hallym University Sacred Heart Hospital), Thanh Trung Nguyen (Hallym University, Hallym University Sacred Heart Hospital), Hye Joung Choi (Hallym University, Hallym University Sacred Heart Hospital), Suk‐Jun Song (Hallym University, Hallym University Sacred Heart Hospital), In Hee Kwak (Hallym University, Hallym University Sacred Heart Hospital), Dong Gyun Ko (Hallym University, Hallym University Sacred Heart Hospital), Jung Hyun Lim (Hallym University, Hallym University Sacred Heart Hospital), Je Kook Yu (Hallym University, Hallym University Sacred Heart Hospital), Hyeo‐Il Ma (Hallym University, Hallym University Sacred Heart Hospital), Yong Wook Kim (Hallym University, Hallym University Sacred Heart Hospital)

Movement Disorders
License: not stated (all rights reserved)

Abstract: BACKGROUND: α-Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α-synuclein seeds can be detected by real-time quaking-induced conversion (RT-QuIC), current assays primarily rely on cerebrospinal fluid, whose invasiveness limits repeated and large-scale applications. We therefore evaluated the feasibility of detecting pathogenic α-synuclein using urine-derived neuronal extracellular vesicles (NEVs). METHODS: Urine-derived NEVs were enriched by direct immunoprecipitation using L1CAM-conjugated magnetic beads. The RT-QuIC assay was performed in 26 patients with PD, 13 with MSA, and 25 disease controls, including 16 healthy controls (HC), 4 with progressive supranuclear palsy (PSP), and 5 with normal pressure hydrocephalus (NPH). RESULTS: Urine-derived NEVs exhibited characteristic neuronal and exosomal markers and a typical extracellular vesicle size distribution. The urine-based RT-QuIC assay distinguished PD from disease controls with 73.1% sensitivity and 84% specificity, and MSA from disease controls with 76.9% sensitivity and 84% specificity. When compared with HC alone, sensitivity and specificity were 73.1% and 93.8% for PD, and 76.9% and 93.8% for MSA, respectively. Kinetic analysis showed higher maximum fluorescence intensity and area under the curve (AUC) in PD compared with both disease controls and HC (P < 0.001 in all). MSA also demonstrated higher maximum fluorescence intensity than HC and increased AUC compared with both disease controls and HC (P < 0.05 in all). CONCLUSIONS: We developed and optimized a completely non-invasive urine-derived NEV α-synuclein RT-QuIC assay that demonstrates high specificity and moderate sensitivity for synucleinopathies. This approach warrants further validation in larger cohorts. © 2026 International Parkinson and Movement Disorder Society.

Published on 21 Sep. 2026